- Genomic signatures help determine which treatment to use in breast cancer
- They prevent many unnecessary chemotherapy and their side effects.
After 9 years of follow-up, European MINDACT confirms prospective study the Lancet Diagnostic utility of the MammaPrint® genomic signature, which allows women suffering from breast cancer to avoid unnecessary chemotherapy.
“De-escalation of chemotherapy”
“We are extremely proud of the publication of the long-term results of MINDACT, a large European study in Lank oncology. They confirm that low genomic risk means low risk, and we can safely suggest de-escalation of chemotherapy . In these patients, especially those over 50 years of age who have traditionally been treated aggressively, including lymph node involvement “,” Congratulations to Martine Piccart, Honorary Professor of Oncology at the Open University of Brussels. “These results support the idea that all patients with early-stage breast cancer should have access to a recurrence risk test – which should be considered the standard of care at diagnosis in all women.” she believes.
What is the access to genomic tests?
Data published in The lancet oncology Show that about half of women with breast cancer who have received chemotherapy can save it without harm. “Community of Breast Cancer Specialists Interested in Understanding the Benefits of Chemotherapy for Premenopausal Women,” Detailed Laura Van’TVeer, MD. “It is useful to trace the trend and its link to ovarian suppression, and to ensure that all women – regardless of their age – have access to genomic testing. This helps doctors and their patients with their cancer. Will allow all management options to be considered. For their genomic profile “, He concluded.
With 60,000 new cases each year, breast cancer ranks first among women with cancer cases, clearly ahead of colorectal cancer and lung cancer. Breast cancer screening (recommended every 2 years for women between 50 and 74 years of age, editor’s note) is all the more interesting because the 5-year survival of affected patients has been improving more: it has been used for patients diagnosed since 1989. Has been more than 80% for those diagnosed between 2005 and 2010, from 1993 to 87%. As a result, the mortality rate associated with breast cancer decreases from year to year.